Beyond Herceptin and Gleevec

Downward, 1984, Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences, Nature, 307, 521, 10.1038/307521a0 Ullrich, 1984, Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells, Nature, 309, 418, 10.1038/309418a0 Alroy, 1997, The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions, FEBS Lett, 410, 83, 10.1016/S0014-5793(97)00412-2 Riese, 1998, Specificity within the EGF family/ErbB receptor family signaling network, Bioessays, 20, 41, 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V Prenzel, 2001, The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification, Endocr Relat Cancer, 8, 11, 10.1677/erc.0.0080011 Slamon, 1987, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science, 235, 177, 10.1126/science.3798106 Chazin, 1992, Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor, Oncogene, 7, 1859 Kumar, 1991, Regulation of phosphorylation of the c-erbB-2/HER2 gene product by a monoclonal antibody and serum growth factor(s) in human mammary carcinoma cells, Mol Cell Biol, 11, 979, 10.1128/MCB.11.2.979 Carter, 1992, Humanization of an anti-p185HER2 antibody for human cancer therapy, Proc Natl Acad Sci USA, 89, 4285, 10.1073/pnas.89.10.4285 Shepard, 1991, Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic, J Clin Immunol, 11, 117, 10.1007/BF00918679 Lane, 2000, ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency, Mol Cell Biol, 20, 3210, 10.1128/MCB.20.9.3210-3223.2000 Molina, 2001, Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells, Cancer Res, 61, 4744 Cobleigh, 1999, Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease, J Clin Oncol, 17, 2639, 10.1200/JCO.1999.17.9.2639 Vogel, 2002, Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer, J Clin Oncol, 20, 719, 10.1200/JCO.20.3.719 Slamon, 2001, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N Engl J Med, 344, 783, 10.1056/NEJM200103153441101 Hudziak, 1989, p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor, Mol Cell Biol, 9, 1165, 10.1128/MCB.9.3.1165 Nicholson, 2001, EGFR and cancer prognosis, Eur J Cancer, 37, S9, 10.1016/S0959-8049(01)00231-3 Kawamoto, 1983, Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody, Proc Natl Acad Sci USA, 80, 1337, 10.1073/pnas.80.5.1337 Mendelsohn, 2001, The epidermal growth factor receptor as a target for cancer therapy, Endocr Relat Cancer, 8, 3, 10.1677/erc.0.0080003 Kris, 2002, A phase II trial of ZD1839 (‘Iressa’) in advanced non-small lung cancer (NSCLC) patients who failed platinum and doctazel-base regimens (IEAL20), Proc Am Soc Clin Oncol, 21, 292a Fukuoka, 2002, Final results from a phase II trial of ZD1839 (‘Iressa’) for patients with advanced non-small cell lung cancer (IDEAL 1), Proc Am Soc Clin Oncol, 21, 298a Johnson DH, Herbst R: ZD1839 (‘Iressa’) in combination with paclitaxel and carboplatin in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC): results from a phase III clinical trial (INTACT 2). Ann Oncol 2002, 13(Suppl.5). Giaccone, 2002, An phase III clinical trial of ZD1839 (‘Iressa’) in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced non-small cell lung cancer (INTACT 1), Ann Oncol, 2002, 40a Homepage of the American Society of Clinical Oncology on World Wide Web URL: http://www.asco.org. Norman, 2001, OSI-774 OSI Pharmaceuticals, Curr Opin Investig Drugs, 2, 298 Pollack, 1999, Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice, J Pharmacol Exp Ther, 291, 739 Kerbel, 2002, Clinical translation of angiogenesis inhibitors, Nat Rev Cancer, 2, 727, 10.1038/nrc905 Millauer, 1996, Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo, Cancer Res, 56, 1615 Giles, 2003, Phase II study of SU5416-a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor-in patients with refractory myeloproliferative diseases, Cancer, 97, 1920, 10.1002/cncr.11315 Fiedler, 2001, A Phase II study with SU5416 in patients with c-kit positive AML, Proc Am Soc Clin Oncol, 20, 288a Wood, 2000, PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration, Cancer Res, 60, 2178 Mendel, 2003, In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship, Clin Cancer Res, 9, 327 George, 2001, Platelet-derived growth factor receptors: a therapeutic target in solid tumors, Semin Oncol, 28, 27, 10.1016/S0093-7754(01)90100-9 Ostman, 2001, Involvement of platelet-derived growth factor in disease: development of specific antagonists, Adv Cancer Res, 80, 1, 10.1016/S0065-230X(01)80010-5 van der Voort, 2000, The hepatocyte growth factor/Met pathway in development, tumorigenesis, and B-cell differentiation, Adv Cancer Res, 79, 39, 10.1016/S0065-230X(00)79002-6 Longati, 2001, Receptor tyrosine kinases as therapeutic targets: the model of the MET oncogene, Curr Drug Targets, 2, 41, 10.2174/1389450013348920 Huang, 2002, Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic, Curr Opin Investig Drugs, 3, 295 Neshat, 2001, Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR, Proc Natl Acad Sci USA, 98, 10314, 10.1073/pnas.171076798 Podsypanina, 2001, An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/− mice, Proc Natl Acad Sci USA, 98, 10320, 10.1073/pnas.171060098 Kim, 2000, Thio- and oxoflavopiridols, cyclin-dependent kinase 1-selective inhibitors: synthesis and biological effects, J Med Chem, 43, 4126, 10.1021/jm000231g Motwani, 1999, Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells, Clin Cancer Res, 5, 1876 Magee, 1999, New insights into the interaction of Ras with the plasma membrane, Cell, 98, 9, 10.1016/S0092-8674(00)80601-7 Dancey, 2002, Agents targeting ras signaling pathway, Curr Pharm Des, 8, 2259, 10.2174/1381612023393071 Betensky, 2002, Influence of unrecognized molecular heterogeneity on randomized clinical trials, J Clin Oncol, 20, 2495, 10.1200/JCO.2002.06.140 Druker, 2001, Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome, N Engl J Med, 344, 1038, 10.1056/NEJM200104053441402 Gorre, 2001, Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification, Science, 293, 876, 10.1126/science.1062538 van’t Veer, 2002, Gene expression profiling predicts clinical outcome of breast cancer, Nature, 415, 530, 10.1038/415530a